TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

NEXT STORY
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
PREV STORY
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results

Investor Conference Call to be Held Today, Tuesday, May 8, 2018 at 8:30am ETNEW ...

author_avatar
NASDAQ Market News

Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology ...

author_avatar
NASDAQ Market News

New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

author_avatar
NASDAQ Market News